 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || BNT164b1 / BioNTech, BNT164a1 / BioNTech
Trial completion date, Trial primary completion date: Safety and Immune Responses After Vaccination With Two Investigational RNA-based Vaccines Against Tuberculosis in Healthy Volunteers (clinicaltrials.gov) - Oct 23, 2024
P1, N=120, Active, not recruiting, Sponsor: BioNTech SE
Trial completion date: Sep 2025 --> Jan 2026 | Trial primary completion date: Sep 2024 --> Jun 2025
- ||| BNT164b1 / BioNTech, BNT164a1 / BioNTech
Enrollment closed: Safety and Immune Responses After Vaccination With Two Investigational RNA-based Vaccines Against Tuberculosis in BCG Vaccinated Volunteers (clinicaltrials.gov) - Aug 26, 2024
P1/2, N=732, Active, not recruiting, Sponsor: BioNTech SE
Trial completion date: Sep 2025 --> Jan 2026 | Trial primary completion date: Sep 2024 --> Jun 2025 Recruiting --> Active, not recruiting
- || BNT164b1 / BioNTech, BNT164a1 / BioNTech
Enrollment closed: Safety and Immune Responses After Vaccination With Two Investigational RNA-based Vaccines Against Tuberculosis in Healthy Volunteers (clinicaltrials.gov) - Jul 11, 2024
P1, N=120, Active, not recruiting, Sponsor: BioNTech SE
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||| BNT164b1 / BioNTech, BNT164a1 / BioNTech
Phase classification, Enrollment change, Trial completion date, Trial primary completion date: Safety and Immune Responses After Vaccination With Two Investigational RNA-based Vaccines Against Tuberculosis in BCG Vaccinated Volunteers (clinicaltrials.gov) - Apr 10, 2024
P1/2, N=732, Recruiting, Sponsor: BioNTech SE
Recruiting --> Active, not recruiting Phase classification: P1 --> P1/2 | N=144 --> 732 | Trial completion date: Sep 2025 --> Feb 2027 | Trial primary completion date: Feb 2025 --> Mar 2026
- || BNT164b1 / BioNTech, BNT164a1 / BioNTech
Enrollment change: Safety and Immune Responses After Vaccination With Two Investigational RNA-based Vaccines Against Tuberculosis in Healthy Volunteers (clinicaltrials.gov) - Feb 15, 2024
P1, N=128, Recruiting, Sponsor: BioNTech SE
Phase classification: P1 --> P1/2 | N=144 --> 732 | Trial completion date: Sep 2025 --> Feb 2027 | Trial primary completion date: Feb 2025 --> Mar 2026 N=96 --> 128
- || BNT164b1 / BioNTech, BNT164a1 / BioNTech
Trial completion date, Trial primary completion date: Safety and Immune Responses After Vaccination With Two Investigational RNA-based Vaccines Against Tuberculosis in Healthy Volunteers (clinicaltrials.gov) - Dec 31, 2023
P1, N=96, Recruiting, Sponsor: BioNTech SE
- || BNT164b1 / BioNTech, BNT164a1 / BioNTech
Trial completion date, Trial primary completion date: Safety and Immune Responses After Vaccination With Two Investigational RNA-based Vaccines Against Tuberculosis in BCG Vaccinated Volunteers (clinicaltrials.gov) - Dec 31, 2023
P1, N=144, Recruiting, Sponsor: BioNTech SE
- || BNT164b1 / BioNTech, BNT164a1 / BioNTech
Trial completion date, Trial primary completion date: Safety and Immune Responses After Vaccination With Two Investigational RNA-based Vaccines Against Tuberculosis in Healthy Volunteers (clinicaltrials.gov) - Oct 3, 2023
P1, N=96, Recruiting, Sponsor: BioNTech SE
N=96 --> 128 Trial completion date: Feb 2026 --> Oct 2025 | Trial primary completion date: Aug 2025 --> Oct 2024
- ||| BNT164b1 / BioNTech, BNT164a1 / BioNTech
Enrollment open: Safety and Immune Responses After Vaccination With Two Investigational RNA-based Vaccines Against Tuberculosis in BCG Vaccinated Volunteers (clinicaltrials.gov) - Aug 16, 2023
P1, N=144, Recruiting, Sponsor: BioNTech SE
Trial completion date: Feb 2026 --> Oct 2025 | Trial primary completion date: Aug 2025 --> Oct 2024 Not yet recruiting --> Recruiting
- ||| BNT164b1 / BioNTech, BNT164a1 / BioNTech
Enrollment open, Trial completion date, Trial primary completion date: Safety and Immune Responses After Vaccination With Two Investigational RNA-based Vaccines Against Tuberculosis in Healthy Volunteers (clinicaltrials.gov) - May 10, 2023
P1, N=96, Recruiting, Sponsor: BioNTech SE
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Trial completion date: Apr 2025 --> Feb 2026 | Trial primary completion date: Oct 2024 --> Aug 2025
- || BNT164b1 / BioNTech, BNT164a1 / BioNTech
Trial completion date, Trial primary completion date: Safety and Immune Responses After Vaccination With Two Investigational RNA-based Vaccines Against Tuberculosis in Healthy Volunteers (clinicaltrials.gov) - Mar 8, 2023
P1, N=96, Not yet recruiting, Sponsor: BioNTech SE
Not yet recruiting --> Recruiting | Trial completion date: Apr 2025 --> Feb 2026 | Trial primary completion date: Oct 2024 --> Aug 2025 Trial completion date: Dec 2025 --> Apr 2025 | Trial primary completion date: Jun 2025 --> Oct 2024
- || BNT164b1 / BioNTech, BNT164a1 / BioNTech
Trial initiation date: Safety and Immune Responses After Vaccination With Two Investigational RNA-based Vaccines Against Tuberculosis in BCG Vaccinated Volunteers (clinicaltrials.gov) - Dec 2, 2022
P1, N=144, Not yet recruiting, Sponsor: BioNTech SE
Trial completion date: Dec 2025 --> Apr 2025 | Trial primary completion date: Jun 2025 --> Oct 2024 Initiation date: Apr 2023 --> Jul 2023
- ||| BNT164b1 / BioNTech, BNT164a1 / BioNTech
New P1 trial: Safety and Immune Responses After Vaccination With Two Investigational RNA-based Vaccines Against Tuberculosis in BCG Vaccinated Volunteers (clinicaltrials.gov) - Sep 21, 2022
P1, N=144, Not yet recruiting, Sponsor: BioNTech SE
- ||| BNT164b1 / BioNTech, BNT164a1 / BioNTech
New P1 trial: Safety and Immune Responses After Vaccination With Two Investigational RNA-based Vaccines Against Tuberculosis in Healthy Volunteers (clinicaltrials.gov) - Sep 13, 2022
P1, N=96, Not yet recruiting, Sponsor: BioNTech SE